Navigation Links
China Medicine Announces Changes to Management Team
Date:12/23/2009

GUANGZHOU, China, Dec. 23 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a developer and leading distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced that Richard P. Wu has resigned as Chief Financial Officer in order to pursue other professional interests. His resignation was effective December 15, 2009.

Mr. Robert Lu was appointed to serve as the Company's Interim Chief Financial Officer until the Company selected a permanent Chief Financial Officer.

Robert Lu has served as the Company's Financial Manager since August 6, 2009. Prior to joining the Company, Mr. Lu served as the International Regional Tax Manager of Hua Wei Technologies Co., Ltd. from October 2006 through August 2009. From August 2003 to September 2006, Mr. Lu served as a financial supervisor for Dongguan Pulse Electronics Co., Ltd. Mr. Lu received his Bachelor's degree in accounting from the Harbin Institute of Technology in 2003. Mr. Lu is a member of the Chinese Institute of Certified Public Accountants (CICPA) and is fluent in English. He will be supported by Ms. Huizhen Yu, the Company's controller.

"We wish Mr. Wu well in his future endeavors and expect a smooth transition of his responsibilities to Mr. Lu, who has been involved with our cash planning, internal and external reporting and tax planning and capital budgeting for the last several months. We will seek to improve our financial management team with a permanent CFO in the months ahead," stated Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation.

About China Medicine Corporation

China Corporation is a developer and leading distributor of prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. China Medicine also has its research and development force for certain products it manufactures through OEM arrangement makes the distribution. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.chinamedicinecorp.com

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward- looking statement to reflect events or circumstances after the date of this release.

    For more information, please contact:

    Company Contact:
     Mr. Robert Lu
     Chief Financial Officer
     China Medicine Corp.
     Tel:   +86-20-8739-1718
     Email: konzern08@163.com

    Investor Relations Contact:
     Mr. Crocker Coulson, President
     CCG Investor Relations
     Tel:   +1-646-213-1915 (NY Office)
     Email: crocker.coulson@ccgir.com
     Web:   http://www.ccgirasia.com

SOURCE China Medicine Corporation


'/>"/>
SOURCE China Medicine Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... YORK , Feb. 23, 2017 /PRNewswire/ ... comprehensive insights on the various drugs being ... report covers all the drugs that are ... & Clinical). The pipeline focuses on novel ... molecules, antibodies, stem cell therapies, recombinant proteins ...
(Date:2/24/2017)... Medivir AB (Nasdaq Stockholm: MVIR) today announced ... Directors that will be submitted to the 2017 Annual ... the company,s three largest shareholders at the end of ... seat on the Nomination Committee, and the Chairman of ... was as follows:  Anders ...
Breaking Medicine Technology:
(Date:2/23/2017)... Boston, MA (PRWEB) , ... February 23, 2017 ... ... Education and Department of Justice jointly issued a letter to withdraw ... in accordance with their gender identity. The guidance issued in May 2016 by ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... Development will host a diverse symposium on “Doping in Sport: How ... and Sheppard Mullin Richter & Hampton LLP. The symposium will be held at ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, ... trials, today announced that Premier Research, a leading clinical development service provider, has ... are becoming increasingly complex, due in part to an array of circumstances including ...
Breaking Medicine News(10 mins):